Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg ELB245 given once daily for 12 weeks (8 + 4 weeks) versus placebo and versus 4mg tolterodine given once daily in patients with incontinent overactive bladder (OAB)

Next Previous
Trial Profile

A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg ELB245 given once daily for 12 weeks (8 + 4 weeks) versus placebo and versus 4mg tolterodine given once daily in patients with incontinent overactive bladder (OAB)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELB 245 (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors elbion NV

    • Most Recent Events

    • 13 Feb 2013 New source identified and integrated (German Clinical Trials Register; DRKS00003997).
    • 07 Aug 2007 Status changed from recruiting to discontinued.
    • 06 Apr 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top